Lenvatinib, a new TKI that targets platelet‐derived growth factor (PDGF) receptor alpha, fibroblast growth factor (FGF) receptors, and vascular endothelial growth factor (VEGF) receptors, has become available as the first‐line treatment in Ad‐HCC worldwide.15, 16. Here, VEGFA is linked to hepatocellular carcinoma.